Compare AIRE & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | ABVC |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 50.5M |
| IPO Year | 2023 | 2009 |
| Metric | AIRE | ABVC |
|---|---|---|
| Price | $0.29 | $1.34 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 57.2K |
| Earning Date | 05-18-2026 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.14 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $948,420.00 | $509,589.00 |
| Revenue This Year | $470.21 | $735.18 |
| Revenue Next Year | $143.58 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.61 |
| 52 Week High | $1.55 | $4.02 |
| Indicator | AIRE | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 33.00 | 32.84 |
| Support Level | $0.14 | $1.15 |
| Resistance Level | $0.35 | $1.52 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 4.05 | 32.36 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.